Atractylodes: A Comprehensive Reference
1. Identity: Botanical Classification, Nomenclature, and Sources
The genus Atractylodes (family Compositae/Asteraceae) comprises eight species of perennial herbs distributed in East Asia, classified into two major groups: Cangzhu and Bai-zhu (common Chinese names). In Western literature and dietary supplement commerce, the genus is usually referred to simply as "Atractylodes," with individual preparations distinguished by species or common Chinese name.
The four species of greatest pharmacological and commercial significance are:
- Atractylodes macrocephala Koidz. — known in Chinese as Bái zhú (白术), or "white atractylodes" or "largehead atractylodes." A perennial herb of the genus Atractylodes whose rhizome is its primary medicinal part.
- Atractylodes lancea (Thunb.) DC. — known as Cāng zhú (苍术), "grey/blue-green atractylodes." A perennial herb belonging to the Asteraceae family.
- Atractylodes chinensis (DC.) Koidz. — also designated under Cāng zhú in Chinese pharmacopeias and often used interchangeably with A. lancea as a source of Cangzhu.
- Atractylodes japonica Koidz. — used in Japanese traditional medicine (Kampo).
Dried rhizomes of five species of Atractylodes (A. japonica, A. macrocephala, A. lancea, A. chinensis, and A. koreana), family Compositae, have been used as crude drugs mainly for the treatment of stomach disorders and for their diuretic properties in Chinese and Japanese traditional medicines.
A. lancea and A. chinensis are perennial plants widely distributed in China, prescribed in the Chinese, Japanese, and Korean Pharmacopoeia as the botanical origins of the crude drug Cangzhu (Sojutsu in Japanese), collectively termed Atractylodis Rhizoma.
Atractylodes macrocephala, commonly referred to as Baizhu, is a perennial herb native to China, primarily cultivated in the Zhejiang, Anhui, and Hunan provinces. The identification of the botanical origins of these crude drugs is generally difficult from their morphological and chemical features alone, and molecular (ITS DNA sequence) methods have been developed to reliably distinguish species.
Common Forms and Preparations
It is often used as medicine and food to invigorate the spleen for strengthening the stomach, dispel dampness for diuresis, and arrest sweating for preventing miscarriage. A. macrocephala was first recorded in the Shennong's Classic of Materia Medica (Shen-Nong-Ben-Cao-Jing) during the Eastern Han Dynasty, and later described in the Compendium of Materia Medica (Ben-Cao-Gang-Mu, the Ming Dynasty) and other texts.
Traditional preparations of the rhizome include:
- Decoction (water-based tea/infusion): the most classical preparation, produced by simmering dried, sliced rhizome in water.
- Stir-frying with wheat bran (Pào Zhì processing): traditionally used in its processed form, commonly achieved by stir-frying raw rhizome with wheat bran — a technique known as Pao-Zhi in TCM, with a long history of use for Chinese Materia Medica.
- Stir-frying with earth: stir-baking with soil is used for enhancing the action of spleen-tonifying and diarrhea-relieving.
- Pills and powders: classical multi-herb formulas such as Si Jun Zi Tang (Four Gentlemen Decoction) and Shen Ling Bai Zhu San are prepared as powders or decoctions.
- Modern preparations: standardized capsule extracts (especially for A. lancea) and concentrated granules have been developed for clinical use.
The rhizome (RAM) is reported to be used in more than 835 TCM preparations, as well as an integral part of more than 4,340 classic prescriptions for treating chronic diseases.
2. Traditional and Historical Use
China
Atractylodes macrocephala (Bai Zhu) is one of the oldest and most frequently used herbs in all of traditional Chinese herbology. Its first recorded mention appears to be in the Divine Husbandman's Classic of the Materia Medica (Shen Nong Ben Cao) from the second century CE. It was recorded for use in the treatment of "wind–cold–dampness" arthralgia, muscle necrosis, spasm, deep-rooted ulcer, excessive internal heat, and indigestion.
Only by the Song Dynasty (c. 1100 CE) did Bai Zhu and Cang Zhu receive separate identities, with Bai Zhu meaning "White Atractylodes" and Cang Zhu "Dark Atractylodes."
Known as Baizhu in China, it has been a cornerstone of Traditional Chinese Medicine for centuries, employed in East Asia — particularly in China, Japan, and Korea — for its health benefits. Historically, Baizhu has been used as a tonic agent to treat various ailments, including gastrointestinal dysfunction, cancer, osteoporosis, obesity, and fetal irritability.
The herb's use in TCM is deeply rooted in its ability to strengthen the spleen and supplement Qi, which are fundamental concepts in TCM for maintaining health and treating disease.
The rhizomes of Atractylodes macrocephala (Baizhu) have long been used in Traditional Chinese Medicine for the treatment of multiple diseases and conditions, including spleen dysfunction, loss of appetite, abdominal distension, diarrhea, dizziness, and heart palpitation.
Ancient Chinese medicine treatises on Atractylodis Macrocephalae Rhizoma indicated that it possessed an expectorant effect. However, in modern times, it is commonly used as a tocolytic agent (to reduce uterine contractions and support pregnancy).
RAM (the rhizome) is considered a functional food, a tonic, and a constituent of various health products purported for promoting digestion, alleviating fatigue, improving sleeping, enhancing immunity, and treating alimentary anemia.
Classical Formulas Containing Atractylodes
Si Jun Zi Tang (Four Gentlemen Decoction) — comprised of ginseng (ren shen), white atractylodes (bai zhu), poria (fu ling), and licorice (gan cao) — is the classic TCM formula for tonifying Spleen Qi and is used widely in clinical practice.
Shen Ling Bai Zhu San (Ginseng, Poria, and Atractylodes Powder), a popular 10-herb TCM formula, is the primary formula for Spleen Qi deficiency with dampness in the form of diarrhea and one of the most common prescriptions for chronic diarrhea, including IBD.
Japan and Korea
Atractylodes lancea is a common medicinal plant used in Traditional Chinese Medicine and in Japanese Kampo practices for a variety of complaints, but primarily as a general tonic and digestive aid. The rhizome of A. lancea has been traditionally used in Chinese medicine for its significant curative effects, which include drying dampness and strengthening the spleen, dispelling wind and cold, and improving eyesight.
3. Key Constituents and Active Compounds
Atractylodes macrocephala (Bai Zhu)
In recent years, more than 120 compounds have been identified in the rhizome. The primary active components have been identified as sesquiterpenoids, polysaccharides, and polyacetylenes.
The rhizome contains a diverse array of bioactive compounds, including sesquiterpenes, flavonoids, polysaccharides, and essential oils. These compounds contribute to various pharmacological effects, including anti-inflammatory, antioxidant, antiemetic, and immunomodulatory activities. Researchers have identified a range of bioactive compounds including sesquiterpenes, polyacetylenes, flavonoids, and polysaccharides, among others.
Atractylenolides (I, II, and III)
Atractylenolides, comprising atractylenolide I, II, and III, represent the principal bioactive constituents of Atractylodes macrocephala. These are eudesmane-type sesquiterpene lactones and are the most extensively studied compounds from this genus. A quantitative study selecting five bioactive components — including atractylenolide I, II, III, eudesma-4(14),7(11)-dien-8-one, and atractylodin — was performed on twenty-six Atractylodes samples of various origins.
The rhizome contains numerous bioactive compounds, not only a variety of small molecules (sesquiterpenoids, triterpenoids, steroids, coumarins, etc.) but also bioactive polysaccharides and glycoproteins. However, the most important small molecule components of A. macrocephala extracts are arguably the compounds named atractylenolides.
Polysaccharides (AMP)
The polysaccharides from A. macrocephala are important medicinal components, mainly composed of glucose (Glc), galactose (Gal), rhamnose (Rha), arabinose (Ara), mannose (Man), galacturonic acid (GalA), and xylose (Xyl). They show valuable bioactivities, including immunomodulatory, antitumour, gastroprotective, intestinal health-promoting, hepatoprotective, and hypoglycaemic activities.
Additional Sesquiterpenoids and Volatile Compounds
Isolated compounds include new nitrogen-containing sesquiterpenoids (atractylenolactam A and B), new sesquiterpene lactones (8-methoxy-atractylenolide V and 15-acetoxyl atractylenolide III), and 12 known analogs. Other identified constituents include atractylon, β-eudesmol, β-elemol, α-curcumene, β-selinene, and humulene.
Atractylodes lancea / A. chinensis (Cang Zhu)
A. lancea is rich in a volatile oil, making up 3.5–7% of the dried rhizome, including atractylodin, β-eudesmol, hinesol, elemol, atractylone, and β-selinene.
Atractylodin and β-eudesmol are bioactive sesquiterpenoids isolated from the rhizomes of Atractylodes lancea, and are the primary active ingredients responsible for the majority of the pharmacological properties of this species.
One prominent sesquiterpenoid found in the A. lancea rhizome is atractylodin (C₁₃H₁₀O). According to the Chinese Pharmacopoeia (2020), the content of atractylodin in the rhizome should be at least 0.30%.
Active constituents identified for anti-hyperglycemic activity include atractans A, B, and C.
4. Established Mechanisms of Action
Anti-Inflammatory Mechanisms
The TLR4/NF-κB, PI3K/Akt, and MAPK signaling pathways primarily mediate the anti-inflammatory effects of the atractylenolides. ATL-I and ATL-III primarily inhibit TLR4/NF-κB, PI3K/Akt, JAK2/STAT3, MAPK, and FPR1/Nrf2 signaling pathways to reduce pro-inflammatory cytokine production and expression of inflammatory factors for the treatment of a variety of inflammatory conditions.
ATL-I and ATL-III act as antagonists of the TLR4 receptor on white blood cells, effectively reducing the release of pro-inflammatory factors by blocking the TLR-4/NF-κB/MAPK pathway.
ATL-I inhibits the phosphorylation of the IκB-α protein, thereby disrupting the activation of NF-κB and its nuclear translocation in response to LPS/MPTP-induced neuroinflammation. Pre-treatment with ATL-I attenuated the inflammatory response in BV-2 cells by abating the nuclear translocation of NF-κB and by inducing heme oxygenase-1 (HO-1).
ATL-III protects PC12 cells from corticosterone-induced injury by inhibiting intracellular Ca²⁺ overloading, inhibiting the mitochondrial apoptotic pathway, and modulating the MAPK/NF-κB inflammatory pathways.
Anticancer Mechanisms
The atractylenolides exhibit a diverse array of pharmacological properties, including anti-inflammatory, anti-cancer, and organ-protective effects. Recent investigations have demonstrated that the anti-cancer activity of the three atractylenolides can be attributed to their influence on the JAK2/STAT3 signaling pathway.
Comprehensive discussions of their antitumorigenic effects and mechanisms include arresting tumor cell cycle progression, inducing programmed cell death (apoptosis, autophagy, and ferroptosis), inhibiting tumor angiogenesis, suppressing tumor migration and invasion, modulating the tumor immune microenvironment, and enhancing the efficacy of other anticancer treatments.
In lung carcinoma studies, ATL-I increased protein levels of caspase-3, caspase-9, and Bax while decreasing expression of Bcl-2 and Bcl-XL. In an in vivo study, ATL-I effectively suppressed tumor growth in transplanted tumor nude mice with upregulation of caspase-3, caspase-9, and Bax and downregulation of Bcl-2 and Bcl-XL.
Immunomodulatory Mechanisms
The polysaccharides from Atractylodes macrocephala (PAM) are immune system enhancers, which can facilitate the proliferation of lymphocytes and stimulate immune cells.
Experimental evidence suggests that AMPs are metabolized by gut microbiota into short-chain fatty acids and other bioactive metabolites that regulate mucosal immunity, enhance epithelial barrier function, and modulate host metabolic pathways.
Gastrointestinal Motility Mechanisms
Administering mice a certain amount of Baizhu water decoction (0.001 g/ml, 0.01 g/ml, and 0.1 g/ml concentrations) markedly sped up the passage of digestive tract contents. Baizhu can improve the small intestinal smooth muscle's capacity to contract, amplify frequency, and prevent hypoxia. It can also speed up the passage of gastrointestinal contents, which may help to regulate Qi.
Pharmacological Properties of Atractylodin and β-Eudesmol (from A. lancea)
The compound β-eudesmol found in A. lancea rhizome has a desensitizing channel blocking action to nicotinic acetylcholine receptors, anti-angiogenic action in vascular endothelium, and neuronal differentiation actions.
β-Eudesmol, a sesquiterpenoid alcohol isolated from Atractylodes lancea, can potentiate succinylcholine-induced neuromuscular blockade, while the potentiating effect is greater in diabetic muscles than in normal ones.
5. Scientific Evidence by Area of Use
5.1 Gastrointestinal Function
The rhizome has been traditionally used for the treatment of various disorders, such as loss of appetite, diarrhea, limb weakness, gastrointestinal dysfunction, immune dysfunction, diabetes, and some chronic inflammatory diseases.
Preclinical evidence: Atractylodes macrocephala has been approved as a functional food by the National Health Commission of the People's Republic of China. The polysaccharides (AMP) have a variety of biological activities, including enhancing immunity, modulating gastrointestinal motility, and decreasing blood glucose levels.
Most AMPs resist digestion in the upper gastrointestinal tract and are fermented by commensal microbiota to yield bioactive metabolites such as short-chain fatty acids (SCFAs), indole derivatives, and secondary bile acids, which influence barrier integrity, mucosal immunity, and host metabolism.
Evidence strength: As of the current literature, this area is supported primarily by animal, in vitro, and mechanistic preclinical studies, together with a long history of traditional use. Robust, large-scale randomized controlled trials (RCTs) in humans specifically evaluating isolated Atractylodes constituents for gastrointestinal outcomes are limited. The evidence for benefit in multi-herb formula contexts (e.g., Shen Ling Bai Zhu San) includes some clinical data, but attributing benefit to atractylodes alone is difficult in compound formulas.
5.2 Immunomodulation
The polysaccharides show valuable bioactivities including immunomodulatory and antitumour effects. Based on their special structure and pharmacological activity, they can also be used as immune adjuvants, natural plant supplements, and vaccine adjuvants.
Human evidence (A. lancea): A randomized placebo-controlled Phase I clinical trial evaluated the immunomodulatory activities of Atractylodes lancea in healthy Thai subjects, published in BMC Complementary Medicine and Therapies (2021). This study — cited in the clinical trial literature as a Phase I safety and immunomodulatory assessment — represents one of the few controlled human trials with this genus.
Evidence strength: Preclinical (in vitro and animal model) evidence for immunostimulation by AMPs is consistent and mechanistically characterized. Human clinical data remain limited and are mostly Phase I in scope; the field lacks large-scale Phase II or III efficacy trials specifically for immunomodulation.
5.3 Anticancer Activity
Atractylenolides (ATs; mainly AT-I, II, and III), as one of the primary active components of Atractylodes macrocephala, have demonstrated significant antitumorigenic effects against various cancer cells in both in vitro and in vivo studies.
In addition to antitumor effects of atractylenolide I on lung cancer cells, ovarian cancer cells, and leukemia cells in vitro, in vivo results show that atractylenolide I significantly inhibited the tumor body of SGC-7901 gastric cancer cells in BALB/C nude mice by increasing the expression of Bax, cleaved caspase-3, and p53, and decreasing the manifestation of Bcl-2 proliferation.
Atractylenolide II significantly induces apoptosis in HGC-27 and AGS gastric cancer cells by deactivating the Ras/ERK and PI3K/AKT signaling pathways.
In a study on colorectal cancer, AT-II or its combination with IFN-γ significantly inhibited the growth and migration abilities of colorectal cancer cells in vitro and in vivo. The biological mechanisms included inhibition of p38 MAPK, FAK, Wnt/β-catenin, Smad, and NF-κB p65/PD-L1 pathways. AT-II combined with IFN-γ significantly inhibited HCT15 xenograft tumor growth and lung metastases in C57BL/6 mice, accompanied by lymphocyte infiltration into the tumor tissues.
Regarding cholangiocarcinoma, atractylodin and β-eudesmol, the major bioactive compounds in Atractylodes lancea, are promising candidates for anti-cholangiocarcinoma. These compounds modulate the Notch signaling pathway and its upstream/downstream molecules in the CCA cell line at the gene and protein expression level; the Notch1 receptor is identified as a key target molecule of their antiproliferative activities against CCA.
Hinesol inhibited the proliferation of A549 and NCI-H1299 (lung cancer) cells in a dose- and time-dependent manner, according to MTT assay. β-Eudesmol exerts anti-tumor and anti-angiogenic activity and can act as a chemosensitizing agent in therapies targeting drug-resistant cancers.
Evidence strength: ATs appear to be safe and reliable candidate anticancer agents in preclinical models, exhibiting potent antitumor efficacy both as monotherapy and in combination regimens. Preliminary clinical data from a small pilot study indicated no signs of toxicity, but more extensive trials are needed to confirm their safety profile in humans. Overall, the anticancer evidence base for atractylenolides is predominantly preclinical (in vitro and rodent in vivo). Human clinical trial data are extremely limited. This should be understood as a serious gap; no pivotal Phase II or III trials have been published demonstrating efficacy in human cancer patients.
5.4 Anti-inflammatory and Inflammatory Bowel Disease
Activation of signaling molecules downstream of TLR4, including NF-κB and those mediated by MAPK kinases such as JNK, ERK, and p38, results in the transcription of numerous pro-inflammatory genes, including TNF-α, IL-6, IL-1β, and COX-2, eliciting ulcerative colitis (UC) inflammatory responses. ATL-I and ATL-III act as antagonists of the TLR4 receptor and effectively suppress the release of pro-inflammatory cytokines by inhibiting the TLR4/NF-κB/MAPK signaling pathway, leading to a significant improvement in UC (in experimental models).
The combination of gut flora balancing, inflammation reduction, and immune system modulation may go some way to explain the beneficial effects White Atractylodes has for sufferers of inflammatory bowel diseases (IBDs) such as ulcerative colitis.
Evidence strength: IBD-related activity is well characterized at the in vitro and animal model level, with mechanistic detail. Clinical trials specifically using isolated Atractylodes preparations for IBD in humans are not yet established in the current published record. The herb figures prominently in multi-herb TCM formulas used clinically for IBD in East Asian contexts, but trial-level evidence supporting atractylodes as a single agent for this indication in humans is preliminary.
5.5 Neuroprotection and CNS Effects
The anti-neuroinflammatory mechanisms of atractylenolide-I (ATR-I) have been investigated in in vivo and in vitro models of Parkinson's disease (PD). ERK and Akt are specific targets of ATR-I in this context.
To screen potential dual-site inhibitors of acetylcholinesterase (AChE), compounds from wild A. macrocephala were evaluated; biatractylenolide II displayed moderate inhibitory activity (IC₅₀ = 19.61 ± 1.11 μg/mL) on AChE.
A study investigated the multi-target mechanisms of Atractylodes macrocephala and its main active component, Atractylenolide III, in mitigating CNS inflammatory responses in pediatric epilepsy via modulation of the NF-κB signaling pathway.
Evidence strength: Strictly preclinical (in vitro and animal model). There are no human clinical trials on atractylodes for neurological conditions published in the peer-reviewed record at this time.
5.6 Antimicrobial Activity
The major eudesmane lactone sesquiterpene atractylenolide I showed strong inhibitory activity against Helicobacter pylori comparable to metronidazole (a positive control). Against three H. pylori strains, atractylenolide I had potent inhibitory effects with MIC₅₀ values ranging from 27.3 to 48.6 μM and MIC₉₀ values from 45.4 to 87.2 μM.
A. japonica has been known to possess a variety of pharmacological properties against arthritis, bronchitis, and respiratory infectious disease, and to contain more than 50 phytochemicals, including atractylon and its derivatives, sesquiterpenoids, and diacetyl atractylodiol.
Evidence strength: This evidence is entirely in vitro. No clinical trials have been conducted on atractylodes for any infectious disease indication.
5.7 Blood Glucose Regulation
Numerous pharmacological experiments, both in vivo and in vitro, have demonstrated that the A. lancea rhizome exhibits liver protection, lowers blood glucose, has diuretic properties, and has anti-hypoxic effects. Active constituents identified for anti-hyperglycemia are atractans A, B, and C.
Evidence strength: Animal study level; no robust human RCT data on atractylodes specifically for glycemic control are established in the published record.
6. Body Systems and Health Areas Associated with Atractylodes
- Gastrointestinal system: Spleen function (TCM), gastric motility, appetite, diarrhea, abdominal distension, inflammatory bowel disease, gut microbiota modulation.
- Immune system: Lymphocyte proliferation, macrophage activation, cytokine modulation, potential as vaccine adjuvant.
- Oncology (preclinical): Multiple cancer cell lines studied including lung, gastric, colorectal, ovarian, leukemia, and cholangiocarcinoma.
- Central nervous system (preclinical): Neuroinflammation, Parkinson's disease models, epilepsy models, acetylcholinesterase inhibition.
- Metabolic: Blood glucose regulation, anti-obesity (animal studies).
- Reproductive/obstetric: Ancient Chinese medicine treatises indicated it possessed an expectorant effect; however, in modern times, it is commonly used as a tocolytic agent (to prevent preterm uterine contractions).
- Antimicrobial: Activity against H. pylori, MRSA (in vitro).
- Musculoskeletal: Historical use in wind-cold-dampness arthralgia.
7. Dosage Forms and Reported Dosages
Dosages reported in traditional and clinical sources:
- Dried rhizome decoction (A. macrocephala): Decoct 6–12 g; 30–60 g in large dosage, stir-baked with bran for enhancing spleen-tonifying and dampness-drying action, and stir-baked with soil for enhancing spleen-tonifying and diarrhea-relieving action.
- Oral decoctions/pills/powders/syrups: The usual oral dose is 10–15 g; this can be up to 30 g if necessary, for preparations such as decoctions, pills, powders, or syrups.
- Phase I clinical trial (A. lancea standardized extract capsule): Group 1 participants received a single oral dose of 1,000 mg of AL or placebo (20:4 participants); Group 2 participants received daily oral doses of 1,000 mg AL or placebo daily for 21 days (20:4 participants). One capsule contained 2.45 mg atractylodin and 4.06 mg β-eudesmol.
It should be noted that dosages described for traditional decoctions and those used in modern pharmaceutical research are not directly comparable due to differences in extraction efficiency, standardization, and formulation.
8. Safety Considerations and Drug Interactions
General Tolerability
Research has shown that chronic use of Atractylodes macrocephala produces no adverse or toxic effects, and PAM (polysaccharides from A. macrocephala) is reported as an effective and safe bioactive component.
In the Phase I human trial of A. lancea standardized extract: the study is reported as the first pharmacokinetics study of Atractylodes lancea in humans, and AL was well tolerated as verified by clinical and laboratory investigations. There was no change in the pharmacokinetics of atractylodin (AL active compound) when given as multiple dosing for 21 days, suggesting no accumulation.
Atractyloside: A Distinct and Serious Safety Concern
A critical safety distinction must be made. Atractyloside is a diterpenoid glycoside that is a naturally occurring compound in Asteraceae plants and must not be confused with the sesquiterpene lactone atractylenolides from A. macrocephala. Atractyloside (ATR) is a diterpenoid glycoside that occurs naturally in Asteraceae plants, many of which are used in foods and ethnomedicines. Its toxicity has caused fatal renal proximal tubule necrosis and/or centrilobular hepatic necrosis in man and farm animals.
Atractyloside poisoning is an infrequent but often fatal form of herbal poisoning, which occurs worldwide but especially in Africa and the Mediterranean regions. The primary mechanism of atractyloside poisoning is known to be inhibition of the mitochondrial ADP transporter. Poisoning in humans may present with either acute hepatic or renal pathology. Atractyloside in large amounts gives rise to massive necrosis, but in vitro studies have shown that at lower doses cells progress to apoptosis.
Importantly, the toxic compound atractyloside is primarily associated with Atractylis gummifera (Mediterranean "bird-lime thistle") and Xanthium species (cocklebur), rather than with the East Asian medicinal Atractylodes species used in TCM. Nonetheless, a GC/MS screening method was developed to detect the presence of ATR in Atractylodes species used in traditional Chinese medicine, evaluating stability and hydrothermal detoxification; the results suggest that degradation of ATR is a way to increase pharmaceutical safety for the Chinese medicinal industries. This implies low levels may occur and that proper processing can reduce risk.
Sesquiterpene Lactone Class Risk
There is a lack of systematic and long-term studies on the safety profile of atractylenolides when used in combination with other drugs, especially standard anticancer medications. As sesquiterpene lactones, atractylenolides carry a theoretical risk for compound-specific adverse effects, such as idiosyncratic reactions or hepatotoxicity, which warrants proactive monitoring in future preclinical and clinical studies.
Cytochrome P450 (CYP) Drug–Drug Interaction Potential
The inhibitory effects of atractylodin and β-eudesmol on human recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 enzymes were investigated; the inhibitory effects of both compounds on all rCYP450s were weak (IC₅₀: 167 to >686 µM). β-Eudesmol showed the most potent inhibitory effect on rCYP2C19 (IC₅₀ = 172.7 µM) and rCYP3A4 (IC₅₀ = 218.6 µM). These in vitro IC₅₀ values are high relative to expected plasma concentrations, suggesting low clinically relevant CYP inhibition at therapeutic doses, though more in vivo human data would be required for definitive conclusions.
Allergy Potential
As a member of the Asteraceae (Compositae) family, atractylodes carries a theoretical cross-reactivity risk for individuals with known sensitivities to other Asteraceae plants such as ragweed, chrysanthemum, marigold, and daisies. This is a class-level consideration applicable to the genus as a whole.
Pregnancy
Atractylodes macrocephala has a traditional context of use in pregnancy as a tocolytic (to prevent miscarriage). However, as with any herb used during pregnancy, the evidence base does not include controlled human trials adequate to define safety. Traditional use in pregnancy should not be extrapolated to endorsement without qualified clinical oversight.
Processing and Preparation Effects
In TCM, herbal medicines are, in most cases, uniquely processed. Although it is thought that processing can alter the properties of herbal medicines to achieve desired functions, increase potency, and/or reduce side effects, the underlying chemical changes remain unclear for most thermally processed Chinese herbal medicines.
References
Go back